Scrip
Generic Lovenox shows US/EU split on data requirements
27 July 2010
Ian Schofield
The US approval of
Sandoz' generic version of
Sanofi-Aventis' antithrombotic Lovenox (enoxaparin sodium) raises a number of questions, not least why the
FDA sees the product as a generic while for the European authorities a low molecular weight heparin (LMWH) is a biosimilar drug requiring clinical...
Please Login to read the full article.
27 July 2010
Ian Schofield
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA lays out its position on generic Lovenox as observers ask, is Copaxone next?
- US judge sets August hearing on Sanofi-Aventis' bid to halt Lovenox generic
- US judge denies Sanofi-Aventis's bid to stop generic rival for Lovenox
- US FDA rejects second Teva petition to block generic Copaxone
FEATURES
- Interview: European Medicines Agency gets serious about its global strategy
- Anti-obesity drugs: an inventor's perspective
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
